Dr. Juhao Yang, Toxicology Project Leader, China Innovation Center of Roche shared: "This meeting is a pivotal moment, bringing together global leaders to tackle the urgent challenge of immunogenicity ...
Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza ...
Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...
Please provide your email address to receive an email when new articles are posted on . A post hoc analysis of phase 3 trial data showed no association of immunogenicity with efficacy or safety for ...
This is an observer-blinded, three-arms study in 376 patients in Chinese individuals aged from 18 to 55 years old who had previously received three doses COVID-19 vaccine. Immunogenicity in terms of ...
Scientists working for Novartis have taken a step forward in better understanding how new classes of biological drugs might affect patients’ immune systems. Paul Wassmann, PhD senior principal ...
Assessing immunogenicity is a cornerstone of modern drug development, especially for biologics and vaccines. Understanding how the immune system interacts with therapeutic agents is essential to ...
As biologics and biosimilars continue to reshape oncology, ensuring their safety and efficacy remains a top priority. In this expert-driven report, Cerba Research examines the latest advancements in ...
Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results